Oncolytics Biotech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCY research report →
Price Chart
About the company
Oncolytics Biotech Inc. , a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
- CEO
- Jared Kelly
- IPO
- 2001
- Employees
- 29
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ONCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.14M
- P/E
- -1.23
- PEG
- 0.26
- P/S
- 0.00
- P/B
- -5.97
- EV/EBITDA
- -0.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 664.95%
- ROIC
- -76107.78%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-28,725,000
- Net Income
- $-28,759,000-26.2%
- EPS
- $-0.41-36.7%
- OCF Growth
- -1.2%
- FCF Growth
- -0.3%
- 52W High
- $1.30
- 52W Low
- $0.33
- 50D MA
- $0.54
- 200D MA
- $0.81
- Beta
- 1.24
- RSI (14)
- 37
- Avg Volume
- 1.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Oncolytics highlighted continued clinical progress for pelareorep in breast, pancreatic, and anal cancers, while reducing quarterly cash burn and extending runway with a new $20 million financing backstop.· May 14, 2025
- Anal cancer data remained encouraging: GOBLET Cohort 4 showed a 33% objective response rate and one complete response lasting more than 15 months.
- Pancreatic cancer enrollment is ongoing in GOBLET Cohort 5 after safety review clearance; the cohort has enrolled more than half of the 30 evaluable patients needed for Stage 1.
- Breast cancer remains a key strategic priority, with management saying two randomized Phase 2 studies support further development and that the next study is expected to use progression-free survival as the primary endpoint.
- The company is actively searching for a new CEO and wants a leader focused on clinical execution and a possible registration-enabling breast cancer study.
- Balance sheet pressure remains, but a $20 million share purchase agreement with Alumni Capital was announced after quarter-end to extend runway.
Oncolytics reported cash and cash equivalents of $15.3 million as of March 31, 2025, and said that provides runway through the third quarter of 2025. Net cash used in operating activities was $6.5 million in Q1 2025 versus $7.5 million a year ago. General and administrative expenses were $3 million, research and development expenses were $4.1 million versus $5.7 million in Q1 2024, and net loss was $6.7 million, or $0.08 per basic and diluted share, versus a net loss of $6.9 million, or $0.09 per share, in Q1 2024. Forward-looking guidance included continued enrollment in GOBLET Cohort 5, initial efficacy data from that cohort later this year and public sharing next year, and a next breast cancer study with progression-free survival as the anticipated primary endpoint; management also noted the $20 million share purchase agreement with Alumni Capital to help extend runway.
Interim CEO Wayne Pisano emphasized that the company is actively searching for a permanent CEO and wants someone with a laser focus on clinical trial execution. He framed pelareorep as a versatile immunotherapeutic with potential across difficult-to-treat cancers, especially pancreatic, breast, and anal cancers, and pointed to KOL support as reinforcing the program’s promise. His tone was upbeat and confident, but centered on execution, data generation, and finding the right long-term leader.
CFO Kirk Look said cash and cash equivalents were $15.3 million at March 31, 2025, with runway through the third quarter of 2025. He noted net cash used in operating activities of $6.5 million, down from $7.5 million last year, driven by lower operating expenditures; G&A was flat at $3 million and R&D fell to $4.1 million from $5.7 million due mainly to reduced manufacturing and clinical trial costs. He also highlighted the $20 million share purchase agreement with Alumni Capital, saying it provides access to capital at the company’s discretion and helps extend runway, and said the company has tapped it a little, in a strategic manner.
Analysts pressed for specifics on the next breast cancer registration-enabling study, including design and whether PFS would be the endpoint; management said it had discussed the study with the FDA previously and does anticipate PFS as the primary endpoint. Questions also focused on pancreatic regulatory strategy, and management said the FDA is aware of the program and has granted fast-track status, but no recent FDA discussions have taken place. On business development, management said it is evaluating both global and regional partnership structures and continues to explore combinations, especially checkpoint inhibitor combinations in pancreatic cancer, where it sees strong translational and clinical synergy.
Management believes pelareorep has multiple shots on goal, with encouraging signals in anal, pancreatic, and breast cancers. The company said breast data from two randomized Phase 2 studies have largely de-risked the program, and pancreatic enrollment is advancing with a path to more data later this year. Support from KOLs, PanCAN funding, and the new capital facility all help sustain development momentum.
The company still has a short cash runway, with cash only through the third quarter of 2025 absent additional financing or capital use from the Alumni facility. Several development paths remain unsettled, including the exact breast cancer registration strategy and whether the pancreatic program can convert into a registrational path. Management also acknowledged the CEO transition is ongoing, which adds execution and leadership uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 116.5%
- Shares Outstanding
- 100.36M
- Float Shares
- 116.90M
of shares held by institutions
78 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sandbox Financial Partners, LLC | 400.00K | ▲ 400.00K |
| Xtx Topco Ltd | 260.90K | ▲ 151.15K |
| Seeds Investor LLC | 258.31K | 0 |
| International Assets Investment Management, LLC | 201.51K | ▲ 250 |
| Connective Capital Management, LLC | 185.71K | ▲ 185.71K |
| Goldman Sachs Group Inc | 169.90K | ▲ 169.90K |
| Larson Financial Group LLC | 168.32K | ▲ 163.32K |
| Tocqueville Asset Management L.P. | 157.00K | ▲ 10.00K |
| Pfg Investments, LLC | 144.76K | ▲ 16.46K |
| Everhart Financial Group, Inc. | 142.34K | ▲ 1.44K |
| Invesco Ltd. | 142.24K | ▲ 41.05K |
| Susquehanna International Group, Llp | 134.13K | ▲ 92.81K |
Held by 1 ETFs
Biggest fund positions in ONCY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | McAdory John Bearden | other | 0 |
| Jun 1, 26 | Glover Stephen C. | other | 0 |
| Mar 11, 26 | Parsons James T. | buy | 10,000 |
| Mar 12, 26 | Kelly Jared | buy | 5,050 |
| Feb 12, 26 | Kelly Jared | buy | 29,500 |
| Feb 11, 26 | Kelly Jared | buy | 5,600 |
| Feb 12, 26 | Look Kirk | buy | 12,000 |
| Feb 12, 26 | Pisano Wayne | buy | 30,000 |
| Feb 12, 26 | Heineman Thomas Charles | buy | 12,132 |
| Feb 12, 26 | Brown Deborah Margaret | buy | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ONCY coverage
Recent articles, reports, and earnings notes.
No research on ONCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONCY report →Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
globenewswire.com · Nov 13
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
globenewswire.com · Nov 11
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
globenewswire.com · Nov 9
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
globenewswire.com · Nov 4
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
globenewswire.com · Oct 27
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
globenewswire.com · Oct 20
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
globenewswire.com · Oct 14
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
globenewswire.com · Oct 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.